• Vaccine Name: C. muridarum MOMP protein vaccine
• Target Pathogen: Chlamydia muridarum
• Vaccine Ontology ID: VO_0011453
• Type: Subunit vaccine
• Status: Research
• Antigen: C. muridarum major outer membrane protein MOMP
• MOMP gene engineering:
  • Type: Recombinant protein preparation
  • Description: Recombinant maltose binding protein-MOMP (MBP-MOMP) was cloned into the bacterial expression vector pMAL-c2, and used to transform Escherichia coli (DH5α[pMMM3]). The MBP-MOMP was purified by passage through a PD-10 column (Amersham Biosciences, NSW, Australia), followed by a Sephadex G-75 column (Sigma–Aldrich) (Skelding et al., 2006).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000143
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001237
• Immunization Route: Intranasal immunization

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Groups of five mice were immunized on days 0, 7, 14, and 35 via either the IN or TCI route. One group of five mice were used as a control, receiving no immunization solution. Mice immunized intranasally were anaesthetised via inhalation of 4% isofluorane (Abbott Australasia, NSW, Australia), and 10 μl of immunization solution containing 100 μg MOMP, admixed with 10 μg CpG-ODN 1826 (5′-TCC ATG ACG TTC CTG ACG TT-3′) (Geneworks, SA, Australia), and 10 μg cholera toxin (Sigma–Aldrich) was gently pipetted onto each nare (5 μl per nare) (Skelding et al., 2006).
• Challenge Protocol: Five days after the final boost, mice were infected intranasally with C. muridarum. Mice were anaesthetised with 4% isoflurane and 10^3 IFUs were gently pipetted onto the nares. Mice were weighed daily for 10 days then sacrificed 10 days post-infection via a sodium pentobarbital overdose (Nembutal, Abbott Australasia). The lungs from the mice were either perfused and fixed for histopathology or collected for determination of C. muridarum levels (Skelding et al., 2006).
• Efficacy: Both intranasal and transcutaneous immunization protected mice against respiratory challenge with Chlamydia (Skelding et al., 2006).
• Host Ifng (Interferon gamma) response
  • Description: Both TCI and IN immunization resulted in greatly increased IFN-γ gene expression in stimulated lymph node cells (stimulated with MOMP) as compared to non-immunized mice (Skelding et al., 2006).
  • Detailed Gene Information: Click Here.
• Host IgA response
  • Description: Both routes of immunization induced a significant MOMP-specific IgA response in serum with the highest IgA response seen in animals immunized intranasally. These results were compared 7 days post-immunization to non-immunized control mice (Skelding et al., 2006).
  • Detailed Gene Information: Click Here.
• Host IgG response
  • Description: Both routes of immunization (TCI and IN) resulted in levels of MOMP-specific IgG in serum that were significantly higher than that in serum of non-immunized control mice. There was no significant difference between serum IgG levels in animals immunized by either route. These results were gathered 7 days post-immunization (Skelding et al., 2006).
  • Detailed Gene Information: Click Here.